NCT03657797View on ClinicalTrials.gov

Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

PHASE2CompletedINTERVENTIONAL

Enrollment

656

Participants

Timeline

Start Date

August 1, 2018

Primary Completion Date

August 23, 2019

Study Completion Date

August 23, 2019

Conditions

Glaucoma, Open-AngleHypertension, Ocular

Interventions

DRUG

NCX 470

NCX 470 Ophthalmic Solution

DRUG

Latanoprost 0.005%

Latanoprost 0.005% Ophthalmic Solution

Trial Locations (1)

78731

Texan Eye, Austin

All Listed Sponsors

lead

Nicox Ophthalmics, Inc.

INDUSTRY

NCT03657797 - Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter